TABLE 3.

Diagnostic Accuracy of Ovarian Cancer Screening Tests by Age and Stage (95% CI)

Screening tests	Sensitivity	Specificity
CA 125*	78.7 (76.7–87.3)	95.3 (91.9–97.5)
Age < 50 y	84.6 (54.6–98.1)	97.6 (93.1–99.5)
Age ≥50 y	78.0 (65.3–87.7)	93.4 (87.5–97.1)
Early stage	64.5 (45.4–80.8)	95.3 (91.9–97.5)
Late stage	90.2 (76.9–97.3)	95.3 (91.9–97.5)
Symptoms index†	64.0 (52.1–74.8)	88.2 (83.6–91.9)
Age < 50 y	84.6 (54.3–98.0)	88.5 (81.5–93.6)
Age ≥50 y	57.6 (44.1–70.4)	88.7 (81.8–93.7)
Early stage	45.2 (27.3–64.0)	88.2 (83.6–91.9)
Late stage	78.0 (62.4–89.4)	88.2 (83.6–91.9)
Composite marker‡	89.3 (80.1–95.3)	83.5 (78.3–87.8)
Age < 50 y	92.3 (64.0–99.8)	82.0 (74.0–88.3)
Age ≥50 y	88.1 (77.1–95.1)	86.3 (79.0–91.8)
Early stage	80.6 (62.5–92.5)	83.5 (79.3–87.8)
Late stage	95.1 (83.5–99.4)	83.5 (79.3–87.8)

95% CI indicates 95% confidence interval.

^*CA 125 dichotomized at the 95th percentile in the screening population. Subjects with a CA 125 value above that threshold were considered to have a positive CA 125 index.

^†The symptoms index was considered positive if the patient had 1 of the following symptoms for < 1 year but it occurred >12 times per month: bloating or increased abdominal size, abdominal or pelvic pain, difficulty eating, or feeling full quickly.

^‡The composite marker was considered positive if the patient had either a positive CA 125 index or a positive symptoms index (or both). Sensitivity = true-positives/(true-positives + false-negatives). Specificity = true-negatives/(true-negatives + false-positives).